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BACKGROUND: Novel therapies are needed to improve the poor prognosis of patients with recurrent and/or metastatic squamous cell
cancer of the head and neck (SCCHN).
METHODS: ADVANTAGE is a phase I/II, multicentre study evaluating the integrin inhibitor cilengitide combined with cetuximab and
platinum-based chemotherapy in patients with recurrent and/or metastatic SCCHN. The phase I part tested cilengitide (500, 1000
and 2000mg) twice weekly with standard doses of cetuximab, cisplatin and 5-fluorouracil.
RESULTS: Ten patients (9 male, 1 female; median 56 years old) were included in the phase I part. No dose-limiting toxicities (DLTs:
grade 3/4 toxicities in the first 3 weeks as defined per protocol) or deaths occurred. The most common adverse events (AEs) were
constipation, rash, nausea, anorexia and fatigue. Cilengitide-related grade 3/4 AEs, all of which occurred after the DLT observation
period, were anaemia, angioedema, asthenia, mucosal inflammation, nausea and vomiting (one event per category). Best overall
tumour response was partial response (PR) for 4 out of 10 patients and stable disease (SD) for 6 out of 10 patients across all cohorts.
Disease control rate (complete response, PR and SD) was 100%.
CONCLUSION: Cilengitide combined with cetuximab and platinum-based chemotherapy was well tolerated. No DLTs or unexpected
AEs were observed. Cilengitide 2000mg was considered safe and was selected for the subsequent randomised phase II part assessing
progression-free survival.
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Most cancers of the head and neck are located in the oral cavity,
pharynx and larynx (National Comprehensive Cancer Network,
2010), and 490% of such cancers are of squamous cell histology
(Marur and Forastiere, 2008; Gregoire et al, 2010). Squamous cell
cancer of the head and neck (SCCHN) accounted for 4.0% of all
cancers worldwide in 2008, with an estimated 498000 new cases
globally in that year (Ferlay et al, 2010).
The prognosis for patients with recurrent and/or metastatic
disease is extremely poor, and has remained largely unchanged in
the past 30 years despite the introduction of new cytotoxic agents.
The treatment goal for recurrent and/or metastatic SCCHN is
symptom management and prolongation of survival (National
Comprehensive Cancer Network, 2010). For those not suitable for
local therapies, treatment options have been limited to systemic
chemotherapy and best supportive care (Langer, 2008). With the
use of platinum-based chemotherapy, median survival time is
typically around 6–8 months (Langer, 2008) and the 1-year
survival rate is 20–40% (Gibson et al, 2005).
The introduction of therapies targeting the epidermal growth
factor receptor (EGFR) has recently improved prognosis in SCCHN
patients. In a large randomised controlled trial published in 2008,
the addition of cetuximab, a monoclonal antibody against EGFR,
to platinum-based chemotherapy was associated with a significant
improvement in overall survival (OS) and progression-free
survival (PFS) and good tolerability, compared with chemotherapy
alone (Vermorken et al, 2008). Median OS was 10.1 months (vs 7.4
months with chemotherapy alone, P¼0.04) and median PFS was
5.6 months (vs 3.3 months with chemotherapy alone, Po0.001)
(Vermorken et al, 2008). This increase in OS time of 2.7 months
was a significant advance in the treatment of SCCHN, but novel
approaches are urgently required to further improve survival
(Bernier, 2009).
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sIntegrins promote and regulate endothelial cell proliferation,
migration, invasion, and survival in tumours, securing vascular-
isation and vascular remodelling in tumours (Garmy-Susini and
Varner, 2008; Desgrosellier and Cheresh, 2010). Squamous cell
cancer of the head and neck is a highly vascularised cancer that
expresses integrins: integrin avb3 is primarily expressed in the
endothelia of SCCHN tumours (Beer et al, 2007; Fabricius et al,
2011) while integrin avb5 is primarily expressed in the tumour
stroma (Fabricius et al, 2011). Cilengitide (EMD 121974, manu-
factured by Merck KGaA, Darmstadt, Germany) is an investiga-
tional cyclic arginine-glycine-aspartic acid (RGD) containing
pentapeptide sequence that selectively inhibits the avb3/5 integrins
(Dechantsreiter et al, 1999). Cilengitide is the first integrin
inhibitor to reach phase III clinical trials in glioblastoma, another
highly vascularised cancer (Stupp et al, 2010b).
ADVANTAGE is a phase I/II trial evaluating cilengitide in
combination with cetuximab, cisplatin and 5-fluorouracil (5-FU)
in patients with recurrent and/or metastatic SCCHN. We report
here the results of the phase I part of the ADVANTAGE study,
which was designed to determine the safety and tolerability of the
combination treatment at increasing doses of cilengitide.
MATERIALS AND METHODS
Study design
The ADVANTAGE trial (ClinicalTrials.gov identifier NCT00705016)
is a phase I/II, multicentre study in patients with recurrent and/or
metastatic SCCHN. The study is divided into two parts: a phase I
part with dose escalation of cilengitide (presented here) and an
open-label, randomised, controlled, phase II part, which is ongoing.
The phase I part aimed to include 9–18 patients, with 3 patients per
cohort, and began in July 2008. The data cutoff point for the safety
results presented here was 1 March 2010.
A3þ3 design was used, consisting of a cohort-wise escalation
of cilengitide in combination with cetuximab, cisplatin and 5-FU
over three cohorts. Patients were observed for dose-limiting
toxicities (DLTs) during the first 3-week cycle of therapy. If there
were no DLTs in the three patients in cohort 1, then cohort 2 could
proceed, but if one of the three patients from cohort 1 experienced
a DLT, then an additional three patients were required to be
evaluated in cohort 1. If a cohort was expanded to six patients in
this way, the next cohort could proceed if p2 of 6 patients
experienced a DLT.
Patients
Inclusion criteria for the study included: (i) adults aged X18 years;
(ii) a histologically or cytologically confirmed diagnosis of
recurrent and/or metastatic SCCHN that was not suitable for local
therapy; (iii) patients with X1 measurable lesion by either
computerised tomography (CT) or magnetic resonance imaging
(MRI); (iv) performance status X70 on the Karnofsky perfor-
mance status scale; and (v) 0–1 on the Eastern Cooperative
Oncology Group scale.
Key exclusion criteria were (i) prior systemic chemotherapy
(unless as part of multimodal treatment for locally advanced disease
completed 46 months before study entry); (ii) surgery (excluding
diagnostic biopsy) or irradiation p4 weeks before study entry;
(iii) nasopharyngeal carcinoma; (iv) active infection, uncontrolled
hypertension, abnormal haematology or liver function; (v) preg-
nancy; (vi) other concomitant anticancer therapies or previous
treatment with EGFR targeting therapy or signal transduction
inhibitors; (vii) brain metastases; and (viii) known drug abuse.
The study was conducted in accordance with the Declaration of
Helsinki and in compliance with Good Clinical Practice. The
protocol was approved by institutional review boards, and all
patients provided written informed consent.
Study intervention
The selection of cilengitide regimens in this study was based on
investigations to date in patients with various cancer diagnoses.
These studies demonstrated that twice weekly cilengitide up to
2400mgm
 2 had antitumour effects and was well tolerated
(Eskens et al, 2003; Nabors et al, 2007).
Patients were given one of three cilengitide doses (500, 1000, or
2000mg) administered intravenously (i.v.) twice a week over 1h,
in combination with standard doses of cetuximab (administered
i.v. at an initial dose of 400mgm
 2 over 2h, followed by weekly
doses of 250mgm
 2 over 1h) and chemotherapy. Chemotherapy
consisted of cisplatin (100mgm
 2 i.v. on day 1) plus 5-FU
(1000mgm
 2 day
 1 continuous infusion from day 1 to 4) during
the first week of each 3-week cycle. Treatment was administered
for up to 6 cycles (i.e., 18 weeks), until progressive disease (PD),
death, unacceptable toxicity or withdrawal of consent. Patients
without progression after six cycles of therapy continued
maintenance treatment with cilengitide plus cetuximab only.
Measured outcomes
The primary objective of the phase I safety run-in was to determine
the safety and tolerability of cilengitide in combination with
cetuximab, cisplatin and 5-FU. The study also examined activity in
terms of response and disease control. Imaging studies, including
CT scans or MRI of the head, neck and chest, were performed at
baseline and every 6 weeks after randomisation until PD. Response
was assessed according to RECIST 1.0 (Therasse et al, 2000).
Disease control rate was defined as the proportion of patients
whose best overall response was confirmed complete response
(CR), partial response (PR) or stable disease (SD).
Safety was assessed by monitoring laboratory parameters, vital
signs and adverse events (AEs) as graded according to the National
Cancer Institute Common Terminology Criteria (NCI CTCAE
v3.0). Treatment-related AEs were defined as AEs that the
investigator deemed related to the investigational medicinal
product or non-investigational medicinal product. Investigators
assessed relatedness of an AE either as ‘related’ or as ‘not related’.
Definition of DLTs
The observation period for DLTs was the first 3 weeks of study
treatment. During that time, DLTs were defined as follows:
  Any grade 3/4 treatment-related toxicity confirmed by the
Safety Monitoring Committee to be relevant. This explicitly
included:
* Any grade 4 haematological or non-haematological toxicity if
not specifically excluded (see below).
* Any treatment-related death observed within the first 3 weeks
of therapy.
  Explicitly excluded from the DLT definition were the following
toxicities that are expected from treatment with cisplatin, 5-FU
or cetuximab:
* Fatigue (lethargy, malaise and asthenia – even if considered
related to cilengitide).
* Alopecia.
* Rash of grades 3 and 4.
* Nausea or vomiting of grades 3 and 4.
* Neutropenia for p5 days and not associated with fever.
* Isolated lymphocytopenia or thrombocytopenia grades 3 and
4 with no clinical correlate.
* Diarrhoea grades 3 and 4 in the absence of supportive care.
* Single laboratory values that were out of the normal range,
without clinical correlate, unlikely to be treatment-related
and spontaneously resolving within 7 days.
* Any hypersensitivity reaction (as this is independent of
dose).
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In total, 10 patients (9 male, 1 female) with a median age of 56
years (range 32–74 years) with recurrent and/or metastatic
SCCHN participated in the phase I part (Table 1). Three patients
were included in cohorts 1 and 2, respectively. Four patients
instead of three were included in cohort 3, as two participants were
screened in parallel and a request to include both in the trial was
accepted. The median treatment duration of cilengitide adminis-
tration was 24.4 weeks (range 12–57 weeks), and all patients
completed at least three treatment cycles (Table 2). One patient
completed three treatment cycles, two patients completed four
treatment cycles and one patient completed five treatment cycles.
Six patients completed all six treatment cycles and four out of the
six patients continued maintenance treatment with cilengitide and
cetuximab. The reasons for study completion/discontinuation were
PD (eight patients), an AE (one patient who had elevated
creatinine levels) and the investigator’s decision (one patient).
Individual patient characteristics are described in Table 3.
Safety and tolerability
All patients (n¼10) experienced at least one AE during the study;
however, the observed AEs were in line with the patients’
underlying disease and the known toxicities of cetuximab and
the concomitant chemotherapies. No DLTs (for DLT definition, see
Measured outcomes section) or deaths were reported for any
patient in any cohort during the phase I component of this study.
The most common AEs of any toxicity grade were constipation,
rash, nausea, anorexia and fatigue (Table 4). Seven patients
experienced an AE assessed as related to cilengitide by the
investigator (one in cohort 1, three in cohort 2 and three in cohort 3).
Of the most common AEs reported (in 42 patients), those
assessed as related to cilengitide were nausea, anorexia, asthenia,
vomiting, mucosal inflammation and dry skin (Table 4).
Grade 3/4 AEs were experienced by all 10 patients, and these
were related to cilengitide in 3 patients (two in cohort 2 and one in
cohort 3). Neutropenia was the most common grade 3/4 AE, but
this was not assessed as related to cilengitide treatment (Table 5).
Anaemia, angioedema, asthenia, mucosal inflammation, nausea
and vomiting were grade 3/4 AEs that occurred after the DLT
observation period and were assessed as related to cilengitide
treatment. The single case of angioedema (of the throat) occurred
10 months after the start of treatment and 2 weeks after the very
last administration of cetuximab and cilengitide. The investigator
assigned angioedema as related to both cetuximab and cilengitide.
However, the day before occurrence of angioedema, bisoprolol had
been started in this patient. While anaphylactoid/anaphylactic
reactions have been reported with cetuximab (Merck Serono,
2010), and angioedema has been observed with agents that have
antiangiogenic properties (Bayer, 2011), the b-blocker bisoprolol is
a known cause of angioedema (Duramed Pharmaceuticals, 2011).
Bisoprolol was stopped the day after onset of angioedema and
angioedema resolved the same day. Only one grade 4 AE occurred
(a decreased neutrophil count in cohort 3) and it was not assessed
by the investigator as related to cilengitide treatment.
The maximum tolerated dose of cilengitide was not reached.
Efficacy parameters
The median PFS with cilengitide in combination with cetuximab
and platinum-based chemotherapy was 5.88 months (95% CI
2.96–10.15). Best overall tumour response summarised in Table 2
was PR for one and three patients in the 1000 and 2000mg groups,
respectively, and SD for three, two and one patients in the 500,
1000 and 2000mg groups, respectively. Disease control rate (CR,
PR and SD) was 100%.
DISCUSSION
This phase I part of a combined phase I/II trial defined cilengitide
2000mg twice weekly as safe when given with cetuximab, cisplatin
and 5-FU for recurrent and/or metastatic SCCHN. Observed AEs
were in line with both the underlying malignant condition and the
known toxicities of cetuximab and concomitant chemotherapy.
The maximum tolerated cilengitide dose was not identified. No
DLTs were observed.
The selection of cilengitide dose and escalation schedule was
based on previous investigations in animal models and in clinical
studies of patients with various types of cancers (Eskens et al,
2003). In nude mice bearing M21-L human melanoma xenografts,
Table 1 Patient demographics
Cohort 1 (n¼3) Cohort 2 (n¼3) Cohort 3 (n¼4)
Cilengitide 500mg 1000mg 2000mg
Median (range) age, years 56 (54–74) 43 (32–59) 57 (49–68)
Male 3 2 4
Female – 1 –
ECOG performance status, n
0 211
1 123
Abbreviation: ECOG¼Eastern Cooperative Oncology Group.
Table 2 Cilengitide exposure and response
Cohort 1 (n¼3) Cohort 2 (n¼3) Cohort 3 (n¼4)
Cilengitide dose 500mg 1000mg 2000mg
Median duration of cilengitide administration (range), weeks 23.3 (14–25) 42.4 (35–57) 16.3 (12–45)
Best overall tumour response, n
Complete response 0 0 0
Partial response 0 1 3
Stable disease 3 2 1
Progressive disease 0 0 0
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soptimal inhibition of tumour growth occurred at 10–15mgkg
 1,
corresponding to peak plasma concentrations of 10.9–12.7mgml
 1.
In a single-agent dose-escalation phase I study of 37 patients with
metastatic solid tumours, pharmacokinetic analysis showed that
these plasma concentrations (11–13mgml
 1) were achieved in
humans at a dose level of 120mgm
 2 (Eskens et al,2 0 0 3 ) .T e nd o s e
levels of cilengitide (30–1600mgm
 2 i.v. twice weekly) were
examined in this study and cilengitide was associated with a good
safety profile. The pharmacokinetic profile of cilengitide was
independent of dose and no DLTs occurred (Eskens et al,2 0 0 3 ) .A
further phase I study in 20 patients with advanced solid tumours
investigated two doses of cilengitide (600 and 1200mgm
 2)
administered i.v. twice weekly for a median number of 20 infusions
per patient (Hariharan et al, 2007). No DLTs were associated with
cilengitide, and it was well tolerated.
Cilengitide has previously been examined in patients with
refractory brain tumours, in a phase I study of 31 paediatric
patients (p21 years old) who received cilengitide at doses of
120–2400mgm
 2 i.v. twice weekly, for up to 52 weeks (MacDonald
et al, 2008). The results were similar to those of the current study,
with no DLTs observed. The twice weekly dosage of 1800mgm
 2
was recommended for the phase II part of the trial (MacDonald
et al, 2008). An open-label phase I study investigated the toxicity
and maximum tolerated dose of cilengitide in 51 adults with
recurrent malignant glioma (Nabors et al, 2007). Based on the data
from previous studies, cilengitide was administered in eight
different doses from 120 to 2400mgm
 2 i.v. twice weekly in
cohorts containing six evaluable patients (Nabors et al, 2007).
There was no evidence of any cilengitide-related acute toxicities
and a maximum tolerated dose was not identified. Some DLTs
occurred and AEs were mostly mild and the majority were not
attributable to cilengitide. Cilengitide was well tolerated up to
doses of 2400mgm
 2. Several phase II trials have investigated the
effects of cilengitide (500 or 2000mg twice weekly) in patients with
newly diagnosed or recurrent glioblastoma (Gilbert et al, 2007;
Reardon et al, 2008; Stupp et al, 2010a). These studies found that
cilengitide was well tolerated, with promising antitumour activity
and no significant reproducible toxicities. The higher dose of
cilengitide (2000mg) was favourable with respect to OS and PFS
and was thus recommended for subsequent trials (Nabors et al,
2007; Reardon et al, 2008; Stupp et al, 2010a).
The rationale for combining cilengitide with cetuximab and
platinum-based chemotherapy was based upon preclinical data
illustrating cross talk between integrins and members of the EGFR























02010001 Male 56 Distant metastasis Liver Unknown T3N2M0 Pharynx 0
02010002 Female 43 Locoregional recurrence Not applicable Well differentiated T1N0M0 Tongue 1
02010003 Male 56 Distant metastasis Liver Moderately differentiated T4N2M1 Pharynx 0
03010001 Male 59 Locoregional recurrence Not applicable Unknown TxNxMx Tongue 1
03010002 Male 68 Locoregional recurrence Not applicable Well differentiated T4N1M0 Pharynx 1
04010001 Male 54 Locoregional recurrence Not applicable Moderately differentiated T4N1M0 Larynx 0
04010002 Male 74 Distant metastasis Lung Poorly differentiated T4N3M1 Pharynx 1
04010004 Male 49 Distant metastasis Cutaneous, skeletal,
lymph nodes
Poorly differentiated T4N3M0 Larynx 1
08010001 Male 32 Distant metastasis Lung, hepatic, kidney Poorly differentiated T1N1M1 Tongue 0
08010002 Male 57 Locoregional recurrence Not applicable Well differentiated T2N2M0 Tongue 1
Abbreviations: ECOG¼Eastern Cooperative Oncology Group; SCCHN¼squamous cell cancer of the head and neck; TNM = tumour node metastasis.
Table 4 Most frequent AEs (reported in 42 out of 10 patients) and most frequent AEs assessed as related to cilengitide (42 out of 10 patients in total)
Most frequent AEs
a,b
Most frequent AEs related
c to cilengitide (n¼10 patients)
a
n¼10 patients Cohort 1 (n¼3) Cohort 2 (n¼3) Cohort 3 (n¼4)
Cilengitide All doses 500mg 1000mg 2000mg
Constipation 8
Rash 7
Nausea 7 0 3 1
Anorexia 7 1 2 1
Fatigue 6
Asthenia 5 0 2 2
Pyrexia 5
Diarrhoea 5





Mucosal inflammation 3 0 1 2





aRegardless of toxicity grade.
bAny AEs, regardless of relatedness to cilengitide.
cInvestigators assessed AEs either as ‘related’ or as ‘not
related’.
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sfamily (Desgrosellier and Cheresh, 2010). Also, there is evidence that
integrin inhibitors may be most effective when combined with
chemotherapies (Abdollahi et al, 2005; Desgrosellier and Cheresh,
2010). Pharmacokinetic analyses are planned for the phase II part of this
study, as well as pharmacodynamic and pharmacogenetic assessments.
Despite recent therapeutic advances such as cetuximab com-
bined with platinum-based chemotherapy, which can extend
survival in patients with recurrent and/or metastatic SCCHN,
patients still have a poor prognosis (Vermorken et al, 2008).
Cilengitide is an integrin inhibitor, with a different mode of action
compared with the other therapeutic agents currently in clinical
practice for the treatment of SCCHN. It is hypothesised that
cilengitide will increase antitumour activity without compromising
safety and tolerability. A case report describes a patient with a
highly proliferative squamous cell carcinoma of the upper left jaw
(Raguse et al, 2004). The patient received 600mgm
 2 cilengitide
i.v. twice weekly in combination with 1000mgm
 2 gemcitabine
twice weekly every 3 weeks for 5 months followed by maintenance
therapy with 600mgm
 2 cilengitide i.v. twice weekly in a clinical
setting (Raguse et al, 2004). The patient remained stable for 12
months and achieved a partial remission, demonstrating the
clinical potential of cilengitide (Raguse et al, 2004).
The current findings of the phase I part of ADVANTAGE are
promising since they demonstrate an acceptable tolerability profile
of cilengitide and absence of DLTs in patients with recurrent and/
or metastatic SCCHN. The randomised phase II part of this trial is
currently investigating PFS in patients with SCCHN treated with
two regimens of 2000mg cilengitide (weekly vs twice weekly
administration) combined with cetuximab, cisplatin and 5-FU,
compared with cetuximab, cisplatin and 5-FU alone. On the basis
of the available preclinical and clinical phase I/II data for
cilengitide in recurrent malignant glioma, and the findings from
this phase I part, two regimens have been selected for the phase II
part of ADVANTAGE: cilengitide 500mg four times a week (week 1)
followed by 2000mg cilengitide (weeks 2 and 3) for group A or
2000mg cilengitide twice weekly for group B.
In conclusion, the current study investigates a combination of
the integrin inhibitor cilengitide with cetuximab and platinum-
based chemotherapy in patients with recurrent or metastatic
SCCHN. In the phase I safety run-in, cilengitide in combination
with cetuximab, cisplatin and 5-FU was well tolerated, associated
with no unexpected AEs and no DLTs, and no maximum tolerated
dose was identified. A dose of cilengitide 2000mg was selected for
the phase II study, which will assess PFS in a larger patient group.
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aAssessed as related to cilengitide: all of these occurred after the DLT observation period.
bSee more detailed information on angioedema in
Results section.
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